AA
NVO

Ancora Advisors’s Novo Nordisk NVO Stock Holding History

Ancora Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Sell
3,102
-108
-3% -$4.64K ﹤0.01% 798
2026
Q1 		$118K Buy
3,210
+829
+35% +$39.3K ﹤0.01% 866
2025
Q4 		$121K Sell
2,381
-556
-19% -$28.4K ﹤0.01% 872
2025
Q3 		$163K Sell
2,937
-250
-8% -$14.6K ﹤0.01% 763
2025
Q2 		$220K Sell
3,187
-50
-2% -$3.4K ﹤0.01% 700
2025
Q1 		$225K Buy
3,237
+425
+15% +$35.1K 0.01% 690
2024
Q4 		$242K Buy
2,812
+319
+13% +$34.5K 0.01% 671
2024
Q3 		$297K Buy
2,493
+325
+15% +$43.3K 0.01% 611
2024
Q2 		$309K Buy
2,168
+65
+3% +$8.61K 0.01% 587
2024
Q1 		$270K Buy
2,103
+181
+9% +$21.5K 0.01% 613
2023
Q4 		$199K Sell
1,922
-616
-24% -$60.9K ﹤0.01% 668
2023
Q3 		$231K Hold
2,538
– – 0.01% 633
2023
Q2 		$205K Hold
2,538
– – 0.01% 644
2023
Q1 		$202K Buy
2,538
+66
+3% +$4.68K 0.01% 640
2022
Q4 		$167K Hold
2,472
– – ﹤0.01% 713
2022
Q3 		$123K Buy
2,472
+100
+4% +$5.36K ﹤0.01% 844
2022
Q2 		$132K Sell
2,372
-164
-6% -$9.1K ﹤0.01% 875
2022
Q1 		$141K Hold
2,536
– – ﹤0.01% 916
2021
Q4 		$142K Hold
2,536
– – ﹤0.01% 918
2021
Q3 		$122K Hold
2,536
– – ﹤0.01% 916
2021
Q2 		$106K Sell
2,536
-888
-26% -$34.4K ﹤0.01% 893
2021
Q1 		$115K Buy
3,424
+1,524
+80% +$54.3K ﹤0.01% 842
2020
Q4 		$66K Sell
1,900
-1,528
-45% -$52.8K ﹤0.01% 825
2020
Q3 		$119K Buy
3,428
+464
+16% +$15.5K ﹤0.01% 690
2020
Q2 		$97K Sell
2,964
-60
-2% -$1.92K ﹤0.01% 720
2020
Q1 		$91K Hold
3,024
– – ﹤0.01% 796
2019
Q4 		$88K Buy
+3,024
New +$83.7K ﹤0.01% 801
2018
Q4 		– Sell
-4,024
Closed -$95K – 1008
2018
Q3 		$95K Buy
+4,024
New +$98.2K ﹤0.01% 764
2017
Q1 		– Sell
-9,500
Closed -$170K – 939
2016
Q4 		$170K Buy
+9,500
New +$172K 0.01% 578

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Ancora Advisors's NVO Position: Q2 2026 in Review

Ancora Advisors reduced its Novo Nordisk (NVO) stake by 3.4% in Q2 2026, selling an estimated $4.64K and leaving 3,102 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #798.

Ancora Advisors first reported a position in NVO in Q4 2016 and has held it in 29 quarters since. The position peaked at $309K in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Ancora Advisors held 3,102 shares of Novo Nordisk worth $149K as of Q2 2026.
  • Ancora Advisors sold 108 Novo Nordisk shares in Q2 2026, an estimated $4.64K.
  • Novo Nordisk made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #798 holding.
  • Ancora Advisors first reported a position in Novo Nordisk in Q4 2016 and has held it in 29 quarters since.
  • Ancora Advisors's Novo Nordisk position peaked at $309K in Q2 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.